From Lab Bench to Global Market: A Practical Playbook for Japan’s Biotech Startups

Japan’s life sciences sector stands at a critical juncture. While its academic achievements — from Nobel Prize-winning discoveries to world-class translational research — are undeniable, too few of its biotech innovations mature into globally competitive companies. The challenge is not invention, but transformation: how to move from discovery to impact in a global market increasingly defined by capital intensity, regulatory complexity, and the race for talent.

At the Support Connected by the Strengthening Program for Pharmaceutical Startup Ecosystem session during BioJapan 2025, experts from the United States and Japan laid out a practical roadmap for turning Japanese biotech potential into international success. Their insights — spanning venture formation, cross-border fundraising, legal structuring, and deal-making — reveal a consistent message: global expansion requires early strategy, local adaptation, and long-term partnerships.

From Invention to Innovation: Turning Biotech & Science into Societal Impact

Miho Sakuma, Co-Founder and Partner at Q Partners, opened the session with a simple but profound question: how can Japan’s world-class science translate into lasting societal value?

Drawing from her experience at McKinsey and now advising startups through Q Partners, Sakuma outlined a four-stage framework for biotech success — from scientific discovery to proof of concept, sustainable business models, and ultimately societal impact. “It’s not just about bringing one more medicine to market,” she said. “We should ask what kind of change this innovation can create for society — like Edison’s lightbulb, which didn’t just illuminate homes, but transformed how people lived.”

Sakuma sees Japan’s scientific foundation as exceptional, yet underleveraged. “If you look at publications, patents, and the number of Nobel laureates, Japan is incredibly strong,” she said. “But when you look at commercialization metrics — late-stage development, valuations, exits — there’s still a gap. We have seeds of innovation, but they’re not yet connected to global needs.”

To bridge that gap, Sakuma identifies three levers: insight, capital, and talent.

• Insight requires both vision and risk-taking. “Japanese startups tend to avoid strategic risk,” she explained. “We often start with what’s familiar — local markets or therapeutic areas we already know — rather than aiming global from day one.”
• Capital demands fluency in global investor expectations. “Many U.S. venture funds already take enormous risks,” she said. “So they’re reluctant to take more by backing unfamiliar founders. Access and understanding are key.”
• Talent involves aligning expertise with stage-specific needs. “You need local talent who understand the regulatory, legal, and business culture where you want to compete,” she added.

Q Partners, co-founded with renowned biotech entrepreneur Dr. Sachiko Kuno, aims to “orchestrate” these elements through personalized support. Their approach combines strategic mentoring, fundraising guidance, and leadership matchmaking — effectively serving as a bridge between Japanese science and U.S. capital ecosystems.

Building the Network: Lessons from California’s Biotech Engine

If Sakuma described the “why” behind global expansion, Joe Panetta, President Emeritus of Biocom California, offered the “how.”

“California’s life sciences ecosystem didn’t grow overnight,” Panetta said. “It took decades of coordinated effort between academia, industry, government, and service providers.” Biocom California, now the largest life science trade association in the U.S., represents over 1,700 companies, ranging from startups to multinationals like Pfizer and Amgen.

Panetta emphasized five “pillars” of a thriving ecosystem: advocacy, capital, community, workforce, and services. Each pillar reinforces the others — a model Japan could emulate as it strengthens its own biotech clusters.

“We don’t just follow legislation; we shape it,” Panetta said, describing Biocom’s advocacy work in Sacramento and Washington, D.C. “We make sure policymakers understand how critical life sciences are to economic growth.”

Biocom also acts as a matchmaker for capital and partnerships, connecting investors with startups through events like the Global Life Science Partnering Conference in La Jolla. “It’s where small biotech founders can sit across the table from heads of global business development,” he said. “Many of our Japanese partners have found it invaluable.”

To help young companies compete, Biocom launched Venture Hub, an online platform linking more than 300 startups with global investors. It’s part of what Panetta calls California’s “open-architecture” innovation model — where investors, researchers, and entrepreneurs collaborate across institutional boundaries.

“A strong ecosystem depends on shared infrastructure, not competition for it,” he added. “That’s something we’ve learned over 30 years in California — and something any country can build if it commits to collaboration.”

Going Global the Right Way: Legal Strategy as Foundation

The path from Tokyo to Boston or San Diego isn’t just scientific — it’s legal. Wayne Elowe, Co-Chair of Greenberg Traurig’s Global Life Sciences and MedTech Group, stressed that legal structure can make or break a startup’s expansion strategy.

“You don’t need to wait until you’re ready to move,” he said. “Start thinking about your global strategy early — it will evolve, but early planning saves time and money.”

Elowe advises many Japanese biotech firms on establishing U.S. subsidiaries, securing venture capital, and managing intellectual property. His message was clear: strategic alignment matters more than speed.

“For startups with limited funding, the key is prioritization,” he said. “Out of five legal tasks, maybe two need to be done now, and three can wait. Good advisors help you decide which is which.”

Among his most practical insights was the importance of incorporating in Delaware, where most U.S. venture investments occur. “Delaware law is familiar to every VC and corporate lawyer,” he explained. “It shortens negotiation time and signals you’re ready for U.S. capital.”

Elowe also warned that cultural adaptation is as vital as compliance. “Be prepared to adapt,” he said. “It doesn’t mean giving up your Japanese identity, but U.S. investors and executives operate differently. The companies that succeed are those that learn to bridge those styles.”

On exit strategy, Elowe outlined three main paths — IPO, M&A, and out-licensing — but urged founders to begin planning long before they think it’s necessary. “An IPO can take up to two years of preparation,” he said. “Even if you’re early, talk to advisors now so you can decide later from a position of strength.”

Partnerships and the Talent Imperative

Closing the session, Kazuhiko Masano, Director at Locust Walk Japan, tied the discussion together with data-driven realism. His firm, a global life science investment bank with offices in Boston, Tokyo, and Beijing, tracks global licensing and M&A trends — and the numbers tell a sobering story.

“Japan’s presence in global deal value is still small,” he said. “Meanwhile, China and South Korea are rapidly increasing their out-licensing and M&A activity. The reason isn’t just funding — it’s talent.”

Masano highlighted that many Chinese biotech founders are fluent in English and have prior experience running ventures in the U.S. “They know how to communicate with global investors and partners,” he said. “That’s an advantage Japan needs to cultivate.”

To compete, Masano proposed three strategic actions:

1. Develop globally minded leadership from the start — founders who think beyond Japan’s domestic market.
2. Establish overseas branches early, even small ones, to build networks and credibility.
3. Create compelling data packages that clearly define unmet needs and evidence-based solutions.

“Sometimes global pharma tells us Japanese startups’ data are not attractive or comprehensive enough,” he said. “That’s not because the science is weak — it’s because the story isn’t told clearly.”

Masano also emphasized timing. “Licensing negotiations usually take six to nine months,” he explained. “If you start fundraising at the same time, you risk missing windows. Synchronizing BD and financing strategies is critical.”

Wayne Elowe (left) and Kazuhiko Masano (right) emphasized the foundations of global readiness, from strong legal structures and cross-border compliance to leadership capable of turning data into compelling stories for investors.

A Roadmap for Japan’s Next Chapter

Across all four speakers, the message was consistent: Japan’s biotech future depends on its ability to connect insight, capital, and talent across borders.

Sakuma framed it as orchestrating invention into innovation. Panetta demonstrated that ecosystems thrive when community replaces competition. Elowe reminded founders that structure and foresight are silent enablers of success. Masano showed that global readiness — linguistic, cultural, and strategic — is as important as scientific excellence.

For Japanese startups aiming to go global, their advice forms a roadmap for beginners and veterans alike:

• Start early: Build global strategy into your company DNA.
• Invest in relationships: With investors, advisors, and regulators — before you need them.
• Think societal impact: Markets reward solutions that change lives, not just products that sell.
• Learn from others: China’s talent mobility, California’s ecosystem, and Europe’s collaborative research networks all offer lessons.
• Bridge science and storytelling: Great data must also tell a compelling narrative to win partners and capital.

As Sakuma summarized, “Japan’s science has everything it needs to make global impact. The question is how we connect the dots — between invention, innovation, and society.”

If Japan succeeds in doing so, its next breakthrough may not just win another Nobel Prize — it could redefine how the world brings science to life.

Related posts:

Decoding the Global Biopharma Network: How Data-Driven Partnering Is Redefining Japan’s Next Move Bridging the Divide: How CRO Partnerships Can Turn Academic Discoveries into Real Drugs One Network, Many Nodes: How Japan’s Drug Discovery Hubs Can Compete Globally in the Next Decade Taiwan’s Semiconductor Industry Steers Global Tech Amidst Economic Headwinds and Regionalization

Author

Bernice Lottering